p16 Stimulates CDC42-Dependent Migration of Hepatocellular Carcinoma Cells

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Chen, Ya Wen ^a,b,c   Chu, Hsiao Chien ^a   Lin, Ze Shiang ^a   Shiah, Wei Jyh ^a   Chou, Chen Pin ^d   Klimstra, David S ^e   Lewis, Brian C ^c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PROTEIN CDC42; PROTEIN P16; RAC1 PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL MIGRATION; CELL STIMULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL CARCINOMA; METASTASIS; MOLECULAR PATHOLOGY; NONHUMAN; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE;

EID: 84880764350     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069389     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90. doi:10.3322/caac.20107. PubMed: 21296855.
2. Farazi PA, DePinho RA, (2006) Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6: 674-687. doi:10.1038/nrc1934. PubMed: 16929323.
3. Robinson WS, (1994) Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. Annu Rev Med 45: 297-323. doi:10.1146/annurev.med.45.1.297. PubMed: 8198385.
4. Buendia MA, (2000) Genetics of hepatocellular carcinoma. Semin Cancer Biol 10: 185-200. doi:10.1006/scbi.2000.0319. PubMed: 10936068.
5. Liew CT, Li HM, Lo KW, Leow CK, Chan JY, et al. (1999) High frequency of p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 18: 789-795. doi:10.1038/sj.onc.1202359. PubMed: 9989830.
6. Matsuda Y, Ichida T, Matsuzawa J, Sugimura K, Asakura H, (1999) p16(INK4) is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology 116: 394-400. doi:10.1016/S0016-5085(99)70137-X. PubMed: 9922321.
7. Lewis BC, Klimstra DS, Socci ND, Xu S, Koutcher JA, et al. (2005) The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol Cell Biol 25: 1228-1237. doi:10.1128/MCB.25.4.1228-1237.2005. PubMed: 15684377.
8. Chen YW, Klimstra DS, Mongeau ME, Tatem JL, Boyartchuk V, et al. (2007) Loss of p53 and Ink4a/Arf Cooperate in a Cell Autonomous Fashion to Induce Metastasis of Hepatocellular Carcinoma Cells. Cancer Res 67: 7589-7596. doi:10.1158/0008-5472.CAN-07-0381. PubMed: 17699762.
9. Quelle DE, Zindy F, Ashmun RA, Sherr CJ, (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000. doi:10.1016/0092-8674(95)90214-7. PubMed: 8521522.
10. Serrano M, Hannon GJ, Beach D, (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707. doi:10.1038/366704a0. PubMed: 8259215.
11. Pomerantz J, Schreiber-Agus N, Liégeois NJ, Silverman A, Alland L, et al. (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723. doi:10.1016/S0092-8674(00)81400-2. PubMed: 9529248.
12. Sharpless NE, (2005) INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 576: 22-38. doi:10.1016/j.mrfmmm.2004.08.021. PubMed: 15878778.
13. Chen YW, Paliwal S, Draheim K, Grossman SR, Lewis BC, (2008) p19Arf inhibits the invasion of hepatocellular carcinoma cells by binding to C-terminal binding protein. Cancer Res 68: 476-482. doi:10.1158/0008-5472.CAN-07-1960. PubMed: 18199542.
14. Hui AM, Sakamoto M, Kanai Y, Ino Y, Gotoh M, et al. (1996) Inactivation of p16INK4 in hepatocellular carcinoma. Hepatology 24: 575-579. doi:10.1002/hep.510240319. PubMed: 8781327.
15. Emig R, Magener A, Ehemann V, Meyer A, Stilgenbauer F, et al. (1998) Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation. Br J Cancer 78: 1661-1668. doi:10.1038/bjc.1998.739. PubMed: 9862580.
16. Milde-Langosch K, Bamberger AM, Rieck G, Kelp B, Löning T, (2001) Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with a more malignant phenotype. Breast Cancer Res Treat 67: 61-70. doi:10.1023/A:1010623308275. PubMed: 11518467.
17. Lee CT, Capodieci P, Osman I, Fazzari M, Ferrara J, et al. (1999) Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 5: 977-983. PubMed: 10353729.
18. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, et al. (2001) Overexpression of the cell cycle inhibitor p16INK4A in high-grade prostatic intraepithelial neoplasia predicts early relapse in prostate cancer patients. Clin Cancer Res 7: 544-550. PubMed: 11297246.
19. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T, (1998) Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 153: 1741-1748. doi:10.1016/S0002-9440(10)65689-1. PubMed: 9846965.
20. Benard V, Bohl BP, Bokoch GM, (1999) Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases. J Biol Chem 274: 13198-13204. doi:10.1074/jbc.274.19.13198. PubMed: 10224076.
21. Benard V, Bokoch GM, (2002) Assay of Cdc42, Rac, and Rho GTPase activation by affinity methods. Methods Enzymol 345: 349-359. doi:10.1016/S0076-6879(02)45028-8. PubMed: 11665618.
22. Lewis BC, Shim H, Li Q, Wu CS, Lee LA, et al. (1997) Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol 17: 4967-4978. PubMed: 9271375.
23. Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, et al. (2010) Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol 23: 1180-1190. doi:10.1038/modpathol.2010.105. PubMed: 20495535.
24. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, et al. (2007) Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res 13: 1133-1139. doi:10.1158/1078-0432.CCR-06-1025. PubMed: 17317821.
25. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, et al. (2003) Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361: 923-929. doi:10.1016/S0140-6736(03)12775-4. PubMed: 12648972.
26. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, et al. (2008) Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68: 6779-6788. doi:10.1158/0008-5472.CAN-08-0742. PubMed: 18701503.
27. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6: 1-6. PubMed: 15068665.
28. Etienne-Manneville S, Hall A, (2002) Rho GTPases in cell biology. Nature 420: 629-635. doi:10.1038/nature01148. PubMed: 12478284.
29. Thiery JP, (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454. doi:10.1038/nrc822. PubMed: 12189386.
30. Lin ZS, Chu HC, Yen YC, Lewis BC, Chen YW, (2012) Krüppel-like factor 4, a tumor suppressor in hepatocellular carcinoma cells reverts epithelial mesenchymal transition by suppressing slug expression. PLOS ONE 7: e43593. doi:10.1371/journal.pone.0043593. PubMed: 22937066.
31. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, et al. (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440. doi:10.1126/science.8153634. PubMed: 8153634.
32. Sherr CJ, (2001) The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2: 731-737. doi:10.1038/35088605. PubMed: 11584300.
33. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, et al. (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8: 27-32. doi:10.1038/ng0994-27. PubMed: 7726912.
34. Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Saito T, et al. (2006) Cytoplasmic, but not nuclear, p16 expression may signal poor prognosis in high-grade astrocytomas. J Neuro Oncol 77: 273-277. doi:10.1007/s11060-005-9037-5.
35. Koch U, Radtke F, (2007) Notch and cancer: a double-edged sword. Cell Mol Life Sci 64: 2746-2762. doi:10.1007/s00018-007-7164-1. PubMed: 17687513.
36. Massagué J, (2008) TGFbeta in Cancer. Cell 134: 215-230. doi:10.1016/j.cell.2008.07.001. PubMed: 18662538.
37. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, et al. (1997) Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15: 2049-2057. doi:10.1038/sj.onc.1201382. PubMed: 9366522.
38. Fåhraeus R, Lane DP, (1999) The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. EMBO J 18: 2106-2118. doi:10.1093/emboj/18.8.2106. PubMed: 10205165.
39. Li L, Lu Y, (2010) Inhibition of Hypoxia-Induced Cell Motility by p16 in MDA-MB-231 Breast Cancer Cells. J Cancer 1: 126-135. PubMed: 20922054.
40. Souza-Rodrígues E, Estanyol JM, Friedrich-Heineken E, Olmedo E, Vera J, et al. (2007) Proteomic analysis of p16ink4a-binding proteins. Proteomics 7: 4102-4111. doi:10.1002/pmic.200700133. PubMed: 17955473.
41. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM, (2004) p27Kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 18: 862-876. doi:10.1101/gad.1185504. PubMed: 15078817.
42. Nguyen L, Besson A, Heng JI, Schuurmans C, Teboul L, et al. (2006) p27kip1 independently promotes neuronal differentiation and migration in the cerebral cortex. Genes Dev 20: 1511-1524. doi:10.1101/gad.377106. PubMed: 16705040.
43. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, et al. (1998) Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nat Med 4: 1449-1452. doi:10.1038/4042. PubMed: 9846587.
44. McAllister SS, Becker-Hapak M, Pintucci G, Pagano M, Dowdy SF, (2003). Novel: 27(kip1) C-terminal scatter domain mediates Rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol 23: 216-228.